Foreign Subsidiaries

Taiho Pharmaceutical of Beijing Co., Ltd. ("Taiho Beijing" below) was established in China in August 2008 as a wholly owned subsidiary of Taiho Pharmaceutical.
Taiho Beijing obtains the approval from authorities in China on anticancer agents researched and developed by Taiho Pharmaceutical, and conducts clinical development and academic advertising with Chinese oncologists. In July 2009, the company put S-1 on the market and is currently developing its business mainly in China's coastal areas.
Aiming to gain broad recognized of Taiho among the Chinese people as a specialized manufacturer of anticancer agents in China, the company will contribute to cancer treatment in China by providing oncologists, other medical care professionals, and patients with drugs to support them in the battle against cancer.

In 2002, Taiho Pharma U.S.A., Inc., was established as the US subsidiary of Taiho Pharmaceutical Co., Ltd., to provide direct management of research and development programs for obtaining marketing approvals of anticancer drugs in US and European markets.
The carefully selected team of professionals maintains close contact with medical professionals and organizations in the US and Europe, while cooperating with Taiho Pharmaceutical staff in Japan, and also develops new drugs, which contribute to cancer treatment throughout the world.